Philadelphia Chromosome
FDA grants accelerated approval to Iclusig for Philadelphia chromosome-positive ALL
The FDA granted accelerated approval to ponatinib with chemotherapy for the treatment of adults with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia, according to a press release.
Healio Minute Podcast, Leukemia Edition: Top Headlines - Week of March 13, 2023
In this edition, outpatient HSCT feasible for older adults; ponatinib for newly diagnosed Ph+ALL; iomab-B may increase transplant access in relapsed/refractory AML and more.
Ponatinib ‘should be considered a standard of care’ for newly diagnosed Ph+ALL
Ponatinib conferred deeper and more durable responses than imatinib in patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia who received either agent in combination with reduced-intensity chemotherapy.
VIDEO: Combining dasatinib with prednisone, blinatumomab appears safe in ALL subtype
Combining the tyrosine kinase inhibitor dasatinib with prednisone and blinatumomab seemed safe in older patients with Philadelphia chromosome-positive acute lymphoblastic leukemia, researchers reported.
VIDEO: Ponatinib dose-optimization beneficial for CML despite cardiac toxicity
In this video, John C. Byrd, MD, a professor at The Ohio State University, discussed a pair of abstracts that looked at the use of ponatinib for Philadelphia chromosome positive ALL and resistant CML. One study looked at dose optimization of ponatinib for patients with CML, which indicated that starting treatment with a higher dose and then titrating down was effective.
FDA grants breakthrough therapy designation to asciminib for CML
The FDA granted breakthrough therapy designation to asciminib for treatment of certain patients with chronic myeloid leukemia.
Asciminib effective, safe as late-line treatment for chronic-phase CML
Asciminib appeared to be more effective than bosutinib for certain patients with chronic-phase chronic myeloid leukemia who had been treated with at least two tyrosine kinase inhibitors, according to results of the phase 3 ASCEMBL study.
Chemotherapy-free induction, consolidation therapy induces molecular response in Ph+ ALL
A chemotherapy-free first-line treatment strategy led to high rates of molecular response and survival among a subset of adults with acute lymphoblastic leukemia, according to study results published in The New England Journal of Medicine.
Asciminib increases major molecular response rate in CML subset
A randomized phase 3 trial designed to evaluate asciminib as treatment for certain patients with chronic myeloid leukemia met its primary endpoint, according to the agent’s manufacturer.
Poor Ph+ ALL outcomes require reexamination of treatment standard
Philadelphia chromosome-positive acute lymphoblastic leukemia is a rare and aggressive form of leukemia characterized by the presence of the BCR-ABL1 fusion.